About Eyesiu

A HEALTHIER LIFESTYLE

"adding life to years"

WEYE - why eyesiu?

New medicines are very expensive and their development is mainly driven by financial incentives. Yet, our society needs treatment options that are affordable and become readily available. Without these, people in need of help will needlessly continue to suffer and experience discomfort.

VISION

Eyesiu shall make available new affordable treatments to patients and consumers aimed at helping to faster and better preventing and reducing (over)sensitive inflammatory processes in the brain, eye, skin and lungs.

MISSION

Eyesiu develops and manufactures innovative products by addressing known disease processes with existing therapeutics or body-own molecules by making effective use of specific delivery technology for these molecules.

WATCH VIDEO shot at

RTL Z's HOW IT'S DONE at the

At the end of August 2020, Eyesiu was in the television show of RTL Z with inspiring entrepreneurial stories, How It's Done.

~

At the company's laboratories located on the Leiden Bio Science Park (LBSP, Netherlands), Pieter J. Gaillard was interviewed about Eyesiu's innovative nanotechnology ("lipid nanoparticles") used in the pharmaceutical industry, which lipid particles the company now also used to make food supplements work faster, better and longer.

" I am inventor and producer of novel products for healthier brains, eyes, skin and lungs."

Welcome message by Pieter J. Gaillard, founder and CEO

Ever since my good friend almost died of a major stroke in 1992, I wake up to give my 100% to create better treatment options for devastating brain diseases. 
   

It is my strong belief that the lives of those affected can be transformed faster and more successful by connecting known disease targets to known compounds through effective use of drug delivery systems. And I created such technologies and products that followed this principle. 

First, I obtained a Master of Science degree in the neurosciences (on cerebrovascular stroke) from Utrecht University (Netherlands) in 1993, followed by a PhD degree in central nervous system (CNS) pharmacology (on cerebrovascular barriers for CNS drugs) from Leiden University (Netherlands) in 2000. Immediately after, I followed my entrepreneurial spirit by quitting my job in academia to secure private funding to realize my ideas. 

This journey was full of joy, excitement, victorious moments, and it never felt like a day of work. I am proud of the creation of new nanomedicine technology and products for patients with devastating brain diseases. This success was possible only because of the dedicated team and organizations who shared my belief and placed their trust in the company and me. It was truly magical, experiencing what a group of inspired people together can accomplish, something that can make a difference in patients’ lives. Later on, I learned that my entrepreneurial logic is based on the 5 principles of "effectuation".

My first biopharmaceutical company in Leiden (Netherlands) pioneered the creation of therapeutics for devastating brain and eye diseases, with clinical stage products for treating brain cancer and multiple sclerosis, and a preclinical program in hereditary retinal degeneration. Nowadays, these products continue their development at global partners (Oncology Venture from Denmark, EnhanX Biopharm from Taiwan, and Mireca Medicines from Germany) so I can make sure that they become available to patients in need. 

In 2014, I started Eyesiu Medicines BV, again in Leiden (Netherlands). The company develops and manufactures products that target inflammatory disorders of the brain, eye, skin and lungs. Most recently, the company launched its first consumer healthcare product, PEArlboost+ spray, which is a truly fantastic nutraceutical that Eyesiu Care has optimised to best support a pain-free lifestyle and healthier brains, eyes, lungs, skin and hair, and is available for consumers on this website. 

Meanwhile, I am also actively involved as sparringpartner for other life science entrepreneurs, former supervisory board member at LEIDEN&PARTNERS, past-president of Rotary Club Leiden,  co-founder of BBBNedwork Foundation, a national (Dutch) network of scientists and physicians on the vasculature in the brain and eyes, and co-founder of SEVBI, a foundation for effective off-label prescription with a focus on amyotrophic lateral sclerosis (ALS).

My urgent focus is always on creating better treatment options for people in need, as flexible, open-minded and collaborative as I can. And I aspire to continue this crucial work with my good friends in business for many years to come.

Thank you for your trust and support, 
Yours truly, 

Pieter J. Gaillard, PhD
Want to join and own shares in the company?
Eyesiu started a public equity crowdfunding campaign on the Eyevestor platform. You can set up an account by clicking the on the Eyevestor logo, study the investment proposition, and invest. There you can access the Pitch Deck, the AFM ("Autoriteit Financiële Markten") information documentation, the actual equity offering and share purchase portal, the legal infrastructure of the offering, the financial information and projections, and an extensive FAQ section which further details the investment proposition. All the documentation is in Dutch language.
Welcome
Eyesiu's products are attractive for a wide range of market segments, both in human and veterinary medicine, and for multiple diseases.

These developments will especially benefit patients, governments and regional companies in emerging economies, while the improved products have the potential to address significant unmet medical needs in established markets.
Advanced delivery technology
The patented delivery technology of Eyesiu is based on lipid (nano)particles composed of a lipophilic agent and a PEGylated lipid mix. The solvent-free lipid particle stably captures the agent and avoids its precipitation in biological fluids. This enables the absorption of the particles and delivery of the agent to target cells. As such, the technology significantly increases the therapeutic or beneficial action and therefore its healthcare effect. 

Partnering
Eyesiu's partnering strategy is to build value with its internal products by finding partners that support its development: either geographically as co-development partnerships or indication-specific by use of a specific formulation. As products move through development towards their intended markets, commercial partnering at (co)development or marketed stage will become part of our strategy if capital needs require such a partner. 

Eyesiu's platform has provided innovative ophthalmology, dermatology, neurology and pulmonology products. Each of these products has different traits to a pharma/biotech company wanting an effective novel product with low development risk in large and growing markets for therapeutics. 

Submit your message:

Share by: